<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03653520</url>
  </required_header>
  <id_info>
    <org_study_id>ANES001</org_study_id>
    <nct_id>NCT03653520</nct_id>
  </id_info>
  <brief_title>Conscious Sedation Efficacy of the MKO Melt (Midazolam, Ketamine, Ondansetron)</brief_title>
  <official_title>Conscious Sedation Efficacy of the Novel Medication, MKO Melt (Midazolam, Ketamine, Ondansetron), During Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avanti Anesthesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avanti Anesthesia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesized that the combination of Valium, Tramadol and Zofran is
      superior to the substantially more expensive MKO melt in patient satisfaction after cataract
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MKO melt is being marketed as an anesthetic medication for cataract surgery that has the
      advantage that it eliminates the need for an IV in 85% of patients although that number was
      established anecdotally. This alternative, however, is very cost limiting.The investigators
      wanted to see if the current regimen (valium only) or a combination similar to the MKO melt
      (valium + tramadol + zofran) are as good if not better than the MKO melt for anesthesia and
      how many patients could have indeed gone with an intravenous line (didn't need any extra
      medications).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Actual">November 4, 2017</completion_date>
  <primary_completion_date type="Actual">November 2, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
    <masking_description>The surgeon was not aware which medication the patient received</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patient who needed additional IV medication for cataract surgery</measure>
    <time_frame>1 day</time_frame>
    <description>Patients who require IV medications for self-reported pain or anxiety during surgery.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">651</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>diazepam only (group 1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are given 5 or 10mg of diazepam for sedation before surgery for sedation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diazepam/tramadol/ondansetron (group 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are given 5 or 10mg of diazepam, 50 or 100mg of tramadol and 4 or 8mg of ondansetron orally before surgery for sedation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MKO only (group 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are given 1 or 2 MKO melts (each contain 3mg midazolam, 25mg ketamine, 2mg ondansetron) sublingually before surgery for sedation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazepam</intervention_name>
    <description>5 or 10mg</description>
    <arm_group_label>diazepam only (group 1)</arm_group_label>
    <arm_group_label>diazepam/tramadol/ondansetron (group 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>50mg or 100mg</description>
    <arm_group_label>diazepam/tramadol/ondansetron (group 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>1 or two tabs</description>
    <arm_group_label>diazepam/tramadol/ondansetron (group 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MKO melt</intervention_name>
    <description>1 or 2 MKO melts</description>
    <arm_group_label>MKO only (group 3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients scheduled to undergo cataract surgery with Drs. Mayo and Wade at Kirby
             Glen Surgery Center

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Patient is not suitable for the medications for reasons such as unsteady gait, cane,
             wheelchair, severe dementia (unable to consent), terminal illness

          -  Allergy to a medication in protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maggie Jeffries, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Avanti Anesthesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Hermann Kirby Glen Surgery Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>August 28, 2018</last_update_submitted>
  <last_update_submitted_qc>August 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Avanti Anesthesia</investigator_affiliation>
    <investigator_full_name>Maggie Jeffries</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diazepam</mesh_term>
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome measures will be available to those who contact primary investigator. We may decide to fully publish data but are undecided.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 3, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT03653520/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 3, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT03653520/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

